Screener
Ionis Pharmaceuticals IONS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Ionis Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
FAQ
- What is Ionis Pharmaceuticals's debt-to-equity?
- Ionis Pharmaceuticals (IONS) reported debt-to-equity of 0.6× in Q2 2026.
- How has Ionis Pharmaceuticals's debt-to-equity changed year-over-year?
- Ionis Pharmaceuticals's debt-to-equity decreased by 52.5% year-over-year, from 1.3× to 0.6×.
- What is the long-term trend for Ionis Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's debt-to-equity has grown at a 62.9% compound annual growth rate (CAGR), from 0.4× to 5×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Ionis Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude